JS
John R Stuelpnagel (Director) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in 10x Genomics, Inc. (TXG). The largest single filing was $1.2M of TXG (20,000 sh across 3 lots, as filed), executed Sep 3. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
2
0 buys · 2 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$2.4M
shares × price, as filed
Last traded
Sep 3
Filed Sep 8
Median ADV $190.4M across their filed names
Open performance→Volume by month
Buys $0
Sells $2.4M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
TXGRecent filings
TXGSALE
10x Genomics, Inc.
View filing →
$1.2M20,000 sh across 3 lots
Exec Sep 3
Filed Sep 8 · 7:00 PM ET TXGSALE 10x Genomics, Inc. View filing → $1.2M
20,000 sh across 2 lots
Exec Aug 11
Filed Aug 13 · 4:11 PM ET